Non-surgical method of treatment for cataract
The invention provides inhibitors of α-crystallin aggregation and methods of using α-crystallin aggregation inhibitors to, e.g., treat or prevent cataracts in a subject having or at risk of developing cataracts. The invention further provides high throughput methods of screening compounds for modulation of protein thermal stability, the method comprising contacting a protein with each of a plurality of test compounds; and (b) measuring the melting transition (T m ) of the protein in the presence of each of the plurality of test compounds, wherein a compound that decreases or increases the apparent T m by at least 2 standard deviations is identified as a pharmacological protein chaperone.
1. A method of reducing aggregation of an α-crystallin protein by at least 5% in an eye of a subject in need thereof, wherein the subject has age-related cataract, diabetic cataract, a hereditary form of cataract, a cataract associated with surgery, a cataract resulting from exposure to radiation, a cataract resulting from a genetic illness, a cataract resulting from an infection, or a cataract resulting from medication, the method comprising administering to an eye of the subject in need thereof an effective amount of a composition comprising a compound represented by the formula:
or a pharmaceutically acceptable salt thereof.